Search results for "Cardiorespiratory Medicine and Haematology"

showing 10 items of 23 documents

Transcriptome-Wide Analysis Identifies Novel Associations With Blood Pressure.

2017

Hypertension represents a major cardiovascular risk factor. The pathophysiology of increased blood pressure (BP) is not yet completely understood. Transcriptome profiling offers possibilities to uncover genetics effects on BP. Based on 2 populations including 2549 individuals, a meta-analyses of monocytic transcriptome-wide profiles were performed to identify transcripts associated with BP. Replication was performed in 2 independent studies of whole-blood transcriptome data including 1990 individuals. For identified candidate genes, a direct link between long-term changes in BP and gene expression over time and by treatment with BP-lowering therapy was assessed. The predictive value of pro…

0301 basic medicineMaleCandidate geneGene ExpressionGenome-wide association studyBlood Pressure030204 cardiovascular system & hematologyCardiorespiratory Medicine and HaematologyCardiovascularLMNATranscriptome0302 clinical medicineRisk FactorsCEBPAGene expression2.1 Biological and endogenous factorsAetiologyGeneticsMyelin and Lymphocyte-Associated Proteolipid ProteinsBlood Pressure ; Gene Expression ; Genome-wide Association Study ; Hypertension ; Transcriptomeblood pressureGenomicsSingle NucleotideLIM Domain Proteinsblood pressure; gene expression; genome-wide association study; hypertension; transcriptomeStrokeHeart DiseaseHypertensionPublic Health and Health ServicesBiomarker (medicine)FemaleEssential HypertensionPoly(ADP-ribose) PolymerasesBiotechnologyAdulthypertensionClinical SciencesNucleoside Transport ProteinsBiologyPolymorphism Single NucleotideArticle03 medical and health sciencesClinical ResearchInternal MedicineGeneticsHumansPolymorphismgenome-wide association studyGene Expression ProfilingHuman GenomeBlood Pressure DeterminationGene expression profiling030104 developmental biologyGood Health and Well BeingCardiovascular System & Hematologygene expressionCCAAT-Enhancer-Binding ProteinsCarrier ProteinstranscriptomeTranscription Factors
researchProduct

Tissue factor prothrombotic activity is regulated by integrin-arf6 trafficking

2017

Objective— Coagulation initiation by tissue factor (TF) is regulated by cellular inhibitors, cell surface availability of procoagulant phosphatidylserine, and thiol-disulfide exchange. How these mechanisms contribute to keeping TF in a noncoagulant state and to generating prothrombotic TF remain incompletely understood. Approach and Results— Here, we study the activation of TF in primary macrophages by a combination of pharmacological, genetic, and biochemical approaches. We demonstrate that primed macrophages effectively control TF cell surface activity by receptor internalization. After cell injury, ATP signals through the purinergic receptor P2rx7 induce release of TF + microvesicles. T…

0301 basic medicinedynaminsIntegrin alpha4CellCardiorespiratory Medicine and Haematology030204 cardiovascular system & hematologyIntegrin alpha4beta1Inbred C57BLTransgenicMicechemistry.chemical_compound0302 clinical medicineAdenosine TriphosphateCell-Derived MicroparticlesReceptors2.1 Biological and endogenous factorsfibrinGene Knock-In TechniquesAetiologyPhospholipidsTumorbiologyChemistryADP-Ribosylation FactorsHematologyPhosphatidylserineCell biologyProtein Transportmedicine.anatomical_structurePhenotypeProteomeextracellular vesiclesCardiology and Cardiovascular MedicinePurinergic P2X7BiotechnologySignal TransductionGenotypeproteomeClinical SciencesIntegrinMice TransgenicFactor VIIaTransfectionExtracellular vesiclesFibrinArticleCell LineThromboplastin03 medical and health sciencesTissue factorCell Line TumormedicineAnimalsHumansBlood CoagulationMacrophagesThrombosisMice Inbred C57BL030104 developmental biologyCardiovascular System & HematologyADP-Ribosylation Factor 6biology.proteinReceptors Purinergic P2X7
researchProduct

May Measurement Month 2018: an analysis of blood pressure screening results from Spain.

2020

Este artículo se encuentra disponible en la siguiente URL: https://academic.oup.com/eurheartjsupp/article/22/Supplement_H/H119/5898732 En este artículo también participan: Fernando Martínez, Blanca Carreras, Bettina de Berardinis, Thomas Beaney, Anca Chis Ster, Neil R. Poulter, Xin Xia y Luis M. Ruilope. Elevated blood pressure (BP) is the single most important contributing risk factor to the global disease burden, leading to over 10 million deaths each year. In Spain, hypertension (HTN) affects around 20% of the adult population and remains the greatest attributable cause of cardiovascular mortality. May Measurement Month (MMM) is a worldwide initiative aimed at increasing awareness of HTN…

Adult populationPrimary careHipertensión - Medición - España.030204 cardiovascular system & hematologyElevated blood03 medical and health sciences0302 clinical medicineEnvironmental healthHipertensiónControlMedicineAcademicSubjects/MED00200Risk factorHypertension - Mensuration - Spain.1102 Cardiorespiratory Medicine and HaematologyDisease burdenCardiovascular mortalitySistema cardiovascularCommunity pharmaciesbusiness.industryPresión sanguínea - Control - España.SangreBlood pressure - Control - Spain.030229 sport sciencesArticlesBlood pressure Control Hypertension screening TreatmentPresión sanguíneaTreatmentBlood pressureCardiovascular System & HematologyHypertension screeningBlood pressureCardiology and Cardiovascular Medicinebusiness
researchProduct

Reduced In Vivo Aortic Uptake of Radiolabeled Oxidation-Specific Antibodies Reflects Changes in Plaque Composition Consistent With Plaque Stabilizati…

2004

Objective— Labeled oxidation-specific antibodies (Ox-AB) detect, quantify, and noninvasively image lipid-rich atherosclerotic lesions. However, it is unknown whether Ox-AB detect plaque stabilization. Methods and Results— The aortic uptake of intravenously injected 125 I-MDA2 (Ox-AB to malondialdehyde [MDA]–low-density lipoprotein [LDL]) was quantitated in: (1) LDL receptor−/− mice with established atherosclerosis continued on Western diet (Progression) or switched to chow (Regression) or chow+vitamins E and C (Regression-VIT) for 6 months; and (2) Watanabe rabbits (3- to 57-months old) with naturally evolved atherosclerotic lesions. In mice, the Progression group had more extensive athero…

AgingPathologyArteriosclerosisCardiorespiratory Medicine and HaematologyCardiovascularIodine RadioisotopesMiceEpitopeschemistry.chemical_compoundAntibody SpecificityMalondialdehydeReceptorsMonoclonal2.1 Biological and endogenous factorsMacrophageAetiologyradionuclideAortaFibrous capAntibodies MonoclonalimagingMalondialdehydeImmunohistochemistryLipoproteins LDLMutant StrainsHeart Diseasemedicine.anatomical_structurelipids (amino acids peptides and proteins)RabbitsCardiology and Cardiovascular MedicineOxidation-ReductionBlood vesselmedicine.medical_specialtyoxidationLipoproteinsClinical SciencesBiologyAntibodiesLDLIn vivomedicine.arterymedicineAnimalsHeart Disease - Coronary Heart DiseaseAortaAtherosclerosisMice Mutant StrainsReceptors LDLRadioimmunodetectionCardiovascular System & HematologychemistryImmunostainingLipoproteinArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.

2021

Abstract Background and aims Central and Eastern Europe (CEE) is a largely understudied region, despite having the highest cardiovascular disease mortality in Europe. This analysis aimed to assess the proportion of patients in CEE who achieved their LDL-C goals based on individual cardiovascular risk recommended by the 2016 and 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines. Methods The DA VINCI study was a cross-sectional observational study of primary and secondary prevention patients receiving lipid-lowering therapy across Europe between June 2017 and November 2018. Results In total, 2154 patients were enrolled from the Czech Republic (n = 509…

COUNTRIESmedicine.medical_specialtyDyslipidaemiaAtherosclerosis; Cardiovascular; Dyslipidaemia; Low-density lipoprotein cholesterolCardiac & Cardiovascular SystemsIMPACTDYSLIPIDEMIACardiovascularGUIDELINESLipid-lowering therapySecondary CareSecondary careRisk FactorsCARDIOVASCULAR RISK-FACTORSMANAGEMENTMedicineHumansLow-density lipoprotein cholesterolCORONARY-HEART-DISEASE1102 Cardiorespiratory Medicine and HaematologyDyslipidemiasSecondary preventionLipid managementScience & Technologybusiness.industryDisease mortality1103 Clinical SciencesAtherosclerosisPREVENTIONLipidsPREVALENCEClinical PracticeEuropeCross-Sectional StudiesTreatment OutcomePeripheral Vascular DiseaseCardiovascular System & HematologyCardiovascular DiseasesFamily medicineEuropean atherosclerosis societyCardiovascular System & CardiologyObservational studyPolandHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineAtherosclerosis
researchProduct

Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23

2021

Abstract Aims  Our objective was to better understand the genetic bases of dilated cardiomyopathy (DCM), a leading cause of systolic heart failure. Methods and results  We conducted the largest genome-wide association study performed so far in DCM, with 2719 cases and 4440 controls in the discovery population. We identified and replicated two new DCM-associated loci on chromosome 3p25.1 [lead single-nucleotide polymorphism (SNP) rs62232870, P = 8.7 × 10−11 and 7.7 × 10−4 in the discovery and replication steps, respectively] and chromosome 22q11.23 (lead SNP rs7284877, P = 3.3 × 10−8 and 1.4 × 10−3 in the discovery and replication steps, respectively), while confirming two previously identif…

Cardiac & Cardiovascular SystemsCardiomyopathy Dilated/genetics[SDV]Life Sciences [q-bio]Signal Transducing/geneticsDilated cardiomyopathyGenome-wide association studyAdaptor Proteins Signal Transducing/genetics030204 cardiovascular system & hematologyTAURINE0302 clinical medicineGWASMedicinePOSITION STATEMENT1102 Cardiorespiratory Medicine and HaematologyGenetics0303 health scienceseducation.field_of_studyGenetic Predisposition to Disease/geneticsAdaptor ProteinsDilated cardiomyopathy4C-sequencingPolymorphism Single Nucleotide/geneticsGenetic risk scoreCardiology and Cardiovascular MedicineLife Sciences & BiomedicineSingle Nucleotide/geneticsCardiomyopathy DilatedCardiomyopathyPopulationLocus (genetics)Single-nucleotide polymorphismPolymorphism Single NucleotideChromosomes03 medical and health sciencesSystolic/geneticsHeart Failure Systolic/geneticsSNPAnimalsHumansGenetic Predisposition to DiseaseAllelePolymorphismeducationImputationAdaptor Proteins Signal Transducing030304 developmental biologyHeart FailureScience & Technologybusiness.industryWORKING GROUP1103 Clinical Sciencesmedicine.diseaseGenetic architectureCardiovascular System & Hematology Dilated cardiomyopathyDilated/geneticsCardiovascular System & Cardiology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessApoptosis Regulatory ProteinsHeart Failure SystolicGenome-Wide Association Study
researchProduct

May the force be with you: Transfer of healthy mitochondria from stem cells to stroke cells

2018

Stroke is a major cause of death and disability in the United States and around the world with limited therapeutic option. Here, we discuss the critical role of mitochondria in stem cell-mediated rescue of stroke brain by highlighting the concept that deleting the mitochondria from stem cells abolishes the cells’ regenerative potency. The application of innovative approaches entailing generation of mitochondria-voided stem cells as well as pharmacological inhibition of mitochondrial function may elucidate the mechanism underlying transfer of healthy mitochondria to ischemic cells, thereby providing key insights in the pathology and treatment of stroke and other brain disorders plagued with…

Cardiorespiratory Medicine and HaematologyMitochondrionRegenerative medicineRats Sprague-Dawley0302 clinical medicineStem Cell Research - Nonembryonic - Humanenergy metabolismStrokeStem CellsBrainCerebral ischemiaMitochondriaStrokeNeurologycellular bioenergeticStem Cell Research - Nonembryonic - Non-HumanStem cellmedicine.symptomCardiology and Cardiovascular Medicine1.1 Normal biological development and functioningClinical SciencesEnergy metabolismregenerative medicineInflammation03 medical and health sciencesUnderpinning researchmedicineAnimalsHumansNeurology & NeurosurgeryAnimalbusiness.industryMechanism (biology)NeurosciencesStem Cell Researchmedicine.diseaseRatsBrain DisordersTransplantationDisease Models AnimalinflammationDisease ModelsCommentarycellular bioenergeticsSprague-DawleyNeurology (clinical)businessNeuroscience030217 neurology & neurosurgerytransplantationJournal of Cerebral Blood Flow & Metabolism
researchProduct

Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

2019

Gislason, Gunnar H/0000-0002-0548-402X; Malynovsky, Yaroslav V/0000-0002-9118-1104; Bhatt, Deepak L./0000-0002-1278-6245; Nikolaev, Konstantin/0000-0003-4601-6203; Sherwood, Matthew/0000-0002-4305-5883; Chumakova, Galina A/0000-0002-2810-6531; Raffel, Owen C/0000-0001-5470-7050; Leonardi, Sergio/0000-0002-4800-6132; Tse, Hung Fat/0000-0002-9578-7808; Reshetko, Olga/0000-0003-3107-7636; Pereira, Helder/0000-0001-8656-4883; Racca, Vittorio/0000-0002-4465-3789; Podoleanu, Cristian/0000-0001-9987-2519; Ersanli, Murat/0000-0003-1847-3087; Muenzel, Thomas/0000-0001-5503-4150; Sandhu, Manjinder/0000-0003-2538-2079; Taskinen, Marja-Riitta/0000-0002-6229-3588; bastos, jose/0000-0002-9526-3123; Manak…

MaleBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.Cardiac & Cardiovascular SystemsMyocardial InfarctionUNIVERSAL DEFINITION030204 cardiovascular system & hematologyTHERAPYDISEASEchemistry.chemical_compound0302 clinical medicineCardiac and Cardiovascular Systems030212 general & internal medicineMyocardial infarctionProspective Studies1102 Cardiorespiratory Medicine and HaematologyOxygen supplyKardiologiBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.CHOLESTEROLMiddle AgedMI typesCardiologyLDL Cholesterol LipoproteinsFemaleCardiology and Cardiovascular MedicineLife Sciences & Biomedicinemedicine.medical_specialty610ODYSSEY OUTCOMES InvestigatorsAntibodies Monoclonal HumanizedCLASSIFICATION03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansddc:610Alirocumab ; MI types ; Mortality ; PreventionMortalityMETAANALYSISAlirocumabAgedScience & TechnologyTask forceCholesterolbusiness.industryEVOLOCUMABPrevention1103 Clinical SciencesCholesterol LDLmedicine.diseaseEvolocumabchemistryCardiovascular System & HematologyCardiovascular System & CardiologyHuman medicinebusinessAlirocumab
researchProduct

Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease : results from the EUROASPIRE IV …

2018

Background: This study aims to assess the cost-effectiveness of optimized guideline adherence in patients with a history of coronary heart disease. Methods: An individual-based decision tree model was developed using the SMART risk score tool which estimates the 10-year risk for recurrent vascular events in patients with manifest cardiovascular disease (CVD). Analyses were based on the EUROASPIRE IV survey. Outcomes were expressed as an incremental cost-effectiveness ratio (ICER). Results: Data from 4663 patients from 13 European countries were included in the analyses. The mean estimated 10-year risk for a recurrent vascular event decreased from 20.13% to 18.61% after optimized guideline a…

MaleCardiac & Cardiovascular SystemsCost effectivenessmedicine.medical_treatmentCost-Benefit AnalysisCoronary DiseaseDisease030204 cardiovascular system & hematology0302 clinical medicineOlder patientsMedicine030212 general & internal medicineguidelinesEUROASPIRE1102 Cardiorespiratory Medicine and Haematologyhealth care economics and organizationsBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Framingham Risk ScoreSecondary preventionASSOCIATIONMiddle AgedhumanitiesCoronary heart diseaseEuropeDENSITY-LIPOPROTEIN CHOLESTEROLPractice Guidelines as TopicTRIALFemaleGuideline AdherenceCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary prevention ; guidelines ; cost-effectiveness ; coronary heart disease ; EUROASPIREsecondary preventionmedicine.drugINTERVENTIONSmedicine.medical_specialtyEZETIMIBEGuidelinesEVENTS03 medical and health sciencesEzetimibeInternal medicineHumansIn patientcoronary heart diseaseBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.cost-effectivenessMETAANALYSISAgedScience & Technologybusiness.industryDecision TreesSMOKING-CESSATIONCoronary heart diseaseTHRESHOLDSCardiovascular System & HematologyCardiovascular System & CardiologySmoking cessationCost-effectivenessbusinessSTATIN TREATMENT
researchProduct

May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension.

2019

Abstract Aims Raised blood pressure (BP) is the biggest contributor to mortality and disease burden worldwide and fewer than half of those with hypertension are aware of it. May Measurement Month (MMM) is a global campaign set up in 2017, to raise awareness of high BP and as a pragmatic solution to a lack of formal screening worldwide. The 2018 campaign was expanded, aiming to include more participants and countries. Methods and results Eighty-nine countries participated in MMM 2018. Volunteers (≥18 years) were recruited through opportunistic sampling at a variety of screening sites. Each participant had three BP measurements and completed a questionnaire on demographic, lifestyle, and envi…

MaleCardiac & Cardiovascular SystemsCross-sectional studyBlood Pressure030204 cardiovascular system & hematologyGlobal Burden of Disease0302 clinical medicineSurveys and QuestionnairesMMM InvestigatorsMass Screening030212 general & internal medicine1102 Cardiorespiratory Medicine and HaematologyAntihypertensive medicationRISKGlobalAwarenessMiddle AgedPREVALENCEHypertensionBlood pressureScreeningRaised blood pressureFemaleCardiology and Cardiovascular MedicineBURDENLife Sciences & BiomedicineControl; GlobalAdultmedicine.medical_specialtyFast Track Clinical ResearchOpportunistic Sampling03 medical and health sciencesInternal medicineControlmedicineSYSTEMATIC ANALYSISMANAGEMENTHumansMass screeningDisease burdenAntihypertensive AgentsScience & Technologybusiness.industryCase-control studyBlood Pressure DeterminationTreatmentEditor's ChoiceBlood pressureRAMADANCross-Sectional StudiesCardiovascular System & HematologyCase-Control StudiesCardiovascular System & CardiologybusinessHypertension Blood pressure Screening Global Treatment ControlEuropean heart journal
researchProduct